CellBio Scientific Acquires BioChain to Strengthen Leadership in Cellular Models and Preclinical Research

NEWARK, Calif., May 1, 2025 /PRNewswire/ -- CellBio Scientific, a premier provider of life science tools, research services, and clinical solutions, today announced the acquisition of BioChain, a leading provider of biospecimen collection, preparation, and analysis.

The acquisition strengthens CellBio Scientific's platform at a pivotal moment in drug discovery and development, as the industry focuses on using human-relevant research models and analyses. The combined platform will be well-positioned to meet growing demand for innovative tools and translational research solutions.

"BioChain has built a strong reputation over decades by delivering reliable, high-quality solutions to the global scientific and medical communities," said Charles Miller, CEO of CellBio Scientific. "This acquisition is highly complementary to our existing capabilities at System Biosciences and Acepix Biosciences. Together, we are building a unified platform that empowers discovery through scientific excellence, operational depth, and customer focus."

BioChain is widely recognized for its expertise in biological sample collection, preparation, and analysis, with a strong foundation in spatial genomics and biospecimen workflows. Its biospecimens are fully consented under IRB approval and products are routinely used by CLIA-certified laboratories, diagnostic test manufacturers, and translational research teams seeking high-quality, regulatory-compliant inputs.

"Joining CellBio Scientific allows BioChain to accelerate its impact while continuing to do what we do best—support life sciences innovation with trusted biospecimen and discovery solutions," said Grace Tian, CEO of BioChain. "This brings new opportunities to serve our customers and collaborate across a broader platform."

BioChain's headquarters and operations will remain in Newark, California. The company's leadership team will continue to guide local operations, with the BioChain CEO now reporting directly to Miller.

This marks CellBio Scientific's third strategic integration since its formation, following the consolidation of System Biosciences (SBI) and Acepix Biosciences in 2024. Together, the platform is uniquely positioned to support the next generation of drug discovery and biomedical innovation.

About CellBio Scientific:

CellBio Scientific is a premier provider of life science tools, research services, and clinical solutions advancing the frontiers of biomedical discovery. Formed through the strategic integration of System Biosciences (SBI), Acepix Biosciences and BioChain, the company offers a comprehensive portfolio spanning biospecimens, spatial biology, extracellular vesicle technologies, gene delivery systems, cell-based models, and preclinical and clinical histopathology services. With a deep commitment to scientific excellence and innovation, CellBio Scientific empowers researchers, biopharma partners, and clinicians to drive breakthroughs in human health.

For more information, contact Matthew Lorence at [email protected].

Contact Information:
CellBio Scientific
Matthew C. Lorence
925-765-8205
[email protected]

SOURCE CellBio Scientific